Gastric adenocarcinoma following CD19-directed chimeric antigen receptor T cell therapy

Ann Hematol. 2023 Feb;102(2):461-462. doi: 10.1007/s00277-022-05045-w. Epub 2022 Nov 16.

Authors

James A Davis^{1

2}, Jagoda Misniakiewicz³, Lindsey Hendrickson⁴, Mary McGann³, Amanda Herbst⁴, Brian T Hess⁴

Affiliations

¹ Department of Pharmacy, The Medical University of South Carolina, Charleston, USA. [email protected].
² MUSC Hollings Cancer Center, 86 Jonathan Lucas St., Suite 219, Charleston, SC, 29425, USA. [email protected].
³ Department of Pharmacy, The Medical University of South Carolina, Charleston, USA.
⁴ Department of Hematology and Bone Marrow Transplantation, The Medical University of South Carolina, Charleston, SC, USA.

PMID: 36385650
DOI: 10.1007/s00277-022-05045-w

No abstract available

Publication types

Letter

MeSH terms

Adenocarcinoma* / therapy
Antigens, CD19
Cell- and Tissue-Based Therapy
Humans
Immunotherapy, Adoptive
Receptors, Antigen, T-Cell / genetics
Receptors, Chimeric Antigen*

Substances

Receptors, Chimeric Antigen
Receptors, Antigen, T-Cell
Antigens, CD19